Search research articles
Contact Us
Filters
Showing results (41-50 of 60) with videos related to
Page
of 6
Sort By:
Current Pharmaceutical Design
|
September 2, 2015
Organic and Inorganic Nanoparticles for Prevention and Diagnosis of Gastric Cancer
Felipe Oyarzun-Ampuero, Ariel Guerrero, Natalia Hassan-Lopez, et al.
Molecular Pharmaceutics
|
October 12, 2020
Poloxamer 188-Coated Ammonium Methacrylate Copolymer Nanocarriers Enhance Loperamide Permeability across Pgp-Expressing Epithelia
Johanna Catalan-Figueroa, Mauricio A García, Pilar Contreras, et al.
Gels (Basel, Switzerland)
|
August 28, 2025
Gelatin-Based Microspheres of Ciprofloxacin for Enhanced Lung Delivery and Biofilm Eradication in <i>Pseudomonas aeruginosa</i> Pulmonary Infections
Luis Monrreal-Ortega, Rocío Iturriaga-Gallardo, Andrea Vilicic-Rubio, et al.
AAPS Pharmscitech
|
May 2, 2025
Application of a Two-Phase Experiment Design and Optimization Method to Formulate Ciprofloxacin-Loaded Bovine Serum Albumin Nanoparticles with High-Entrapment Efficiency for Targeting Urinary Tract Infections
Sofía V Sánchez, Erlen Cruz Jorge, Nicolás Navarro M, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 30, 2012
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)
Eduardo Gotuzzo, Martin Markowitz, Winai Ratanasuwan, et al.
The AAPS Journal
|
February 15, 2017
Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes
Javier O Morales, Kristin R Fathe, Ashlee Brunaugh, et al.
Theranostics
|
October 4, 2018
Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches
Julian Bejarano, Mario Navarro-Marquez, Francisco Morales-Zavala, et al.
Journal of the International AIDS Society
|
November 14, 2014
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients
Josep M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 10, 2009
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients
Edwin Dejesus, Benjamin Young, Javier O Morales-Ramirez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 30, 2006
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 60) with videos related to
Sort By:
Page
of 6
Current Pharmaceutical Design
|
September 2, 2015
Organic and Inorganic Nanoparticles for Prevention and Diagnosis of Gastric Cancer
Felipe Oyarzun-Ampuero, Ariel Guerrero, Natalia Hassan-Lopez, et al.
Molecular Pharmaceutics
|
October 12, 2020
Poloxamer 188-Coated Ammonium Methacrylate Copolymer Nanocarriers Enhance Loperamide Permeability across Pgp-Expressing Epithelia
Johanna Catalan-Figueroa, Mauricio A García, Pilar Contreras, et al.
Gels (Basel, Switzerland)
|
August 28, 2025
Gelatin-Based Microspheres of Ciprofloxacin for Enhanced Lung Delivery and Biofilm Eradication in <i>Pseudomonas aeruginosa</i> Pulmonary Infections
Luis Monrreal-Ortega, Rocío Iturriaga-Gallardo, Andrea Vilicic-Rubio, et al.
AAPS Pharmscitech
|
May 2, 2025
Application of a Two-Phase Experiment Design and Optimization Method to Formulate Ciprofloxacin-Loaded Bovine Serum Albumin Nanoparticles with High-Entrapment Efficiency for Targeting Urinary Tract Infections
Sofía V Sánchez, Erlen Cruz Jorge, Nicolás Navarro M, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 30, 2012
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)
Eduardo Gotuzzo, Martin Markowitz, Winai Ratanasuwan, et al.
The AAPS Journal
|
February 15, 2017
Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes
Javier O Morales, Kristin R Fathe, Ashlee Brunaugh, et al.
Theranostics
|
October 4, 2018
Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches
Julian Bejarano, Mario Navarro-Marquez, Francisco Morales-Zavala, et al.
Journal of the International AIDS Society
|
November 14, 2014
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients
Josep M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 10, 2009
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients
Edwin Dejesus, Benjamin Young, Javier O Morales-Ramirez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 30, 2006
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, et al.
Page
of 6